Semaglutide

“Yes. So it went through phase three trial. So as of the recording of this episode, it's not FDA approved yet, but it probably will be. And it did cause a little bit more weight loss than the generation two Tirzepatide or one, you know, Semaglutide. But no, it also caught, you also saw muscle loss in the trial.”

“I can tell you after my surgery, my doctor heart did big on the protein. When I started the shots, I started on Semaglutide and I really didn't listen to that. I was just so excited to be losing weight that I didn't count protein. You know, I just, I wasn't hungry. I didn't eat.”

“I'm sure there are, but I'm not aware of them. I'm not deeply familiar with them, but I believe that semaglutide may be FDA approved in some populations of teenagers, but I don't remember the specific parameters for that.”

“And then everything changed when Novo's data came out with semaglutide, which was amazing. It was the first really effective obesity medical therapeutic.”

“when you took Bimagrumab with Semaglutide or Tirzepatide or Liraglutide. It did them all. And the efficacy was sort of unprecedented, never seen. For both fat loss and obviously for preservation of lean mass.”

“Tide is peptide. But were they forced into liraglutide, semaglutide, tirzepatide? The tide is the same. It's going to be for that class, but there are other peptides that end in tide.”

“do a bigger study. We're going to do it in combination with semaglutide. And this was during the pandemic. So there was a lot of complexity and supply chain disruptions. And remember, with semaglutide, it was a proprietary drug of Novo.”

“We couldn't make a placebo for that. So the study design included semaglutide as open label, but we did placebo-controlled bimagrumab because we had control of that.”

“We ended up doing something called a full factorial design. So we did all possible combinations of low-dose semaglutide, high-dose semaglutide, low-dose Bimagrumab, high-dose Bimagrumab in placebo. So it's a nine-arm study.”

“Technically, actually, and we had to do this because we weren't using the semaglutide in its intended population. I think it wasn't registered yet, I guess, was the issue.”

“And we know what happens when you withdraw semaglutide, right? Everything goes back towards where it was, doesn't quite get there. And we're going to find out with Bimagrumab. I expect some things are going to reverse.”

“Now, the problem with coming off of them is, especially with the original drugs, like Semaglutide, an example, right? Where when you lose weight, about a third of the weight you lose would be lean mass, right?”

“This would be amazing. And I mean, in rodent models, it's phenomenal because we did these trials where you randomize mice to get semaglutide, high-dose semaglutide, much higher than you get for a human, and then the transgene, right? And both groups lose weight.”

“If anything, body, body dysmorphia is on the rise, right? And we have some of these things like Ozempic and semaglutide and stuff like that. Really scary. A lot of people don't realize. I'm going off, off. Oh, dude. I'm fucking loving this. You're cooking. Keep going.”

“And so everyone wants to be thin and everyone wants to be beautiful. And like social media is a big part of that. Yep. So then along comes a medication, which is amazing, because this medication makes it so that you don't want to eat. So this is what's really scary about society.”

“And what scares me about semaglutide is up until now, if you wanted to be healthy, if you wanted to have, if you wanted to lose weight, if you wanted to get fit, it required you to put in a certain amount of effort.”

“And along comes semaglutide and these GLP-1 agonists. And suddenly, you don't have to work to get something. You take an injection and then your cravings get reduced.”

“can really control, which is yourself. That's the only thing you can control. And here we are having a lot of people offering us solutions that semaglutide is a great example, remove the need to work on yourself.”

“They're not the same thing. Tirzepatide, semaglutide, they're not the same. They all have different penetrations to the CNS. Okay. So where all of these GLPs go is actually different. So if you look at studies on reductions in alcohol cravings and alcohol addiction, they're not the same for all GLPs because they have different CNS penetration.”

“we were already seeing the effects of semaglutide and how different it was, this was now the third generation of GLP-1 agonists”

“We definitely are. And the Trump RX has lowered a lot of these prices by the way, for a lot of these drugs. Now that time there was a shortage of semaglutide and then eventually Tirzepatide. So the compound pharmacy game shifted boy, the pressure was on.. into making these drugs, compounded versions. So they're not the FDA approved versions, but when there's a shortage of a medication,”

“which I don't think is a good practice, the clinician gets a price from the pharmacy. So the pharmacy will tell you, hey, a vial of semaglutide costs 150 bucks. This clinician can now sell that vial to the patient. Sell, it's really, they're charging an administrative fee, right? It's not a sale because technically you get cell medications.”

“So you have your, you know, semaglutide, which is Ozempic and Wegovy. The Wegovy is the FDA approved version for the weight loss.”

“So we had seen the effects on diabetics and then you get liraglutide, dilutide, and then eventually semaglutide is the blockbuster. But you get all these positive effects coming from these drugs on diabetics. It gets translated into obese people and overweight patients. The question is, what is the long-term effect of this?”

“leading to the hyperglycemia that defines the diabetic state. At this low dose, semaglutide inhibits the alpha cell. It inhibits glucagon. And by inhibiting glucagon, you're helping correct blood glucose. So it was an effective anti-diabetic.”

“Now that is itself a big pool, but some of it would be muscle and bone mass, but I have not seen data that has determined whether it is a direct effect of the semaglutide. In other words, is the drug actually harming muscle and bone or is it just an artifact of the poor nutrition?”